Outstanding Milestone Achieved with SynCardia Total Artificial Heart
Picard Medical, Inc. (NYSE American: PMI), along with its subsidiary SynCardia Systems LLC, has celebrated a significant achievement in the realm of cardiac health. A patient has achieved the remarkable feat of living over eight years, specifically 2,900 days, with the SynCardia™ Total Artificial Heart (STAH). This milestone marks the longest recorded time a patient has relied on an artificial heart, a testament to both the technology and the dedicated medical teams behind it.
Impact of the SynCardia Total Artificial Heart
According to Patrick NJ Schnegelsberg, CEO of Picard Medical, this achievement serves as a clear reflection of the transformative impact of the SynCardia Total Artificial Heart. It not only acts as a bridge to heart transplantation but also provides reliable, long-term support for patients awaiting donor hearts. The durability and resilience of the STAH have made it an essential solution for patients who otherwise have limited options. Currently, Picard Medical is working on developing the Emperor, a next-generation fully implantable artificial heart system aimed at expanding access to life-saving technology and enhancing support capabilities for countless patients globally.
Patient Journey and Success in Clinical Trials
The patient in question, a 46-year-old individual, received the SynCardia Total Artificial Heart in December 2017, at a crucial time when they were facing end-stage heart failure. This procedure took place at the Institute for Cardiovascular Diseases, known as IVDK Dedinje Hospital. Remarkably, eight years on, this patient continues to thrive, with most days spent in the comfort of their home, surrounded by family. This highlights the inclusive and supportive role of medical professionals along with the effectiveness of SynCardia's technology in enhancing life quality.
Leading the World in Heart Support Technology
Serbia has emerged as a leader in providing long-duration support with the SynCardia Total Artificial Heart. The nation is home to the five longest-supported patients in the world, with exemplary cases witnessed at IVDK Dedinje Hospital. These remarkable patients demonstrate a range of support durations, showcasing the hospital's advanced clinical program, driven by committed cardiac surgeons and transplant teams who have elevated the use of the SynCardia technology to an outstanding level.
About Picard Medical and SynCardia
Picard Medical is a pioneer in artificial heart technology, positioning itself as a leader through innovation and quality in the medical field. The SynCardia Total Artificial Heart is recognized globally as the only commercially available total artificial heart system for end-stage heart failure patients. It has gained FDA and Health Canada approval, setting the standard for artificial hearts and becoming the most extensively used and studied of its kind. With over 2,100 implants performed across 27 countries, it continues to advance cardiac care worldwide.
Looking Ahead: Future Innovations
As Picard Medical forges ahead, numerous opportunities for growth and innovation lie before it. The development of their next-generation artificial heart is a testament to the company's commitment to enhancing patient lifespans and quality of life while expanding the availability of life-saving heart technology to an even broader patient population. This focus on innovation and access will undeniably shape the future of cardiac health.
Frequently Asked Questions
What is the SynCardia Total Artificial Heart?
The SynCardia Total Artificial Heart is an implantable device designed to replace the function of a failing human heart, providing essential support for patients with end-stage heart failure.
How long can patients live with the SynCardia heart?
A patient has recently celebrated living over 2,900 days with the SynCardia Total Artificial Heart, showcasing its potential for long-term support.
Where was the SynCardia heart developed?
SynCardia Systems, LLC is based in Tucson, Arizona, and is the leading developer of artificial heart technology worldwide.
What future innovations are coming from Picard Medical?
Picard Medical is actively developing the Emperor, a fully implantable artificial heart system aimed at expanding patient access and options for heart support.
What distinguishes Picard Medical’s technology?
Picard Medical's SynCardia Total Artificial Heart is the only total artificial heart approved by both the FDA and Health Canada, making it a leader in cardiac health technology.
